MARKET

PTN

PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5850
-0.0112
-1.88%
Closed 17:45 02/19 EST
OPEN
0.6000
PREV CLOSE
0.5962
HIGH
0.6000
LOW
0.5810
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
1.780
52 WEEK LOW
0.5800
MARKET CAP
134.11M
P/E (TTM)
4.194
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PTN News

  • Mid-stage study underway evaluating Palatin's PL9643
  • Seeking Alpha - Article.19h ago
  • Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
  • PR Newswire.1d ago
  • Wells cuts view on Teladoc in premarket analyst action
  • Seeking Alpha - Article.02/12 13:08
  • Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript
  • Seeking Alpha - Transcript.02/11 21:55

More

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.22%

Hot Stocks

Name
Price
%Change

About PTN

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
More

Webull offers Palatin Technologies, Inc. (PTN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.